Cardiol Therapeutics Inc (id:13795 CRDL)
2.26 CAD
Opening hours: 09:30 - 16:00 (Eastern Standard Time: 11/23/2024 9:03:45 AM)
Exchange closed, opens in 2 days
About Cardiol Therapeutics Inc
Market Capitalization 208.51M
Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product candidate is CardiolRx, which is in Phase II multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis. The company is also developing CRD-38 injection for subcutaneous administration that is in preclinical development for the treatment of heart failure. It has a license agreement with Meros. The company was incorporated in 2017 and is headquartered in Oakville, Canada.
| Headquarters (address) |
2265 Upper Middle Road East Oakville L6H 0G5 ON Canada |
| Phone | 289-910-0850 |
| Website | https://www.cardiolrx.com |
| Employees | 0 |
| Sector | Healthcare |
| Industry | Drug Manufacturers Specialty & Generic |
| Ticker | CRDL |
| Exchange | Toronto Stock Exchange |
| Currency | CAD |
| 52 week range | 1.07 - 4.26 |
| Market Capitalization | 208.51M |
| P/E trailing | -4.53 |
| P/E forward | -6.09 |
| Price/Book | 11.80 |
| Beta | 0.697 |
| EPS | -0.440 |
| EPS Canada (ID:82, base:722) | 1.84 |